Merck Presents P-III (3475A-D77) Trial Data of SC Keytruda for NSCLC at ELCC 2025
Shots: The P-III (
Johnson & Johnson Reports P-III (MARIPOSA) Trial Data of Rybrevant + Lazcluze for EGFRm NSCLC
Shots: J&J reported P-III (
Axsome Therapeutics Reports P-III (FOCUS) Trial Data of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD)
Shots: Axsome Therapeutics has reported P-III (FOCUS) trial data assessing solriam...
Accent Therapeutics to Highlight Preclinical Data of ATX-559 and ATX-295 at AACR 2025
Shots: Accent Therapeutics to present preclinical data of ATX-559 (DHX9 inhibitor)...
AstraZeneca to Highlight Tagrisso’s Clinical Data for NSCLC at ELCC 2025
Shots: AstraZeneca to present Tagrisso’s data from P-III (
Novartis Reports P-III (STEER & STRENGTH) trials data of OAV101 IT for Spinal Muscular Atrophy
Shots: The sham-controlled P-III (STEER) & open-label P-IIIb (STRENGTH) trials...
